Trial Profile
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Vedolizumab
- Indications Psoriasis
- Focus Pharmacodynamics; Pharmacogenomic; Proof of concept
- Acronyms STRAUSS
- 21 Aug 2018 New trial record